ASAnnalisa Scopinaro

Annalisa Scopinaro

*This is an algorithmically generated author record based on publicly available information.

Annalisa Scopinaro has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The patient’s perspective in the pharmaceutical regulatory and access pathway: considerations and recommendations from the 2025 Patient Forum

    by Claudio Jommi, Fabio Amanti, Oriana Ciani, Francesco Damele, Massimo Di Maio, Antonella Di Lorenzo, Elisabetta Iannelli, Anna Lisa Mandorino, Andrea Marcellusi, Viviana Ruggieri, et al.

    Introduction: Despite the growing attention on Patient-Reported Outcome (PRO) and Patient-Reported Experience (PRE), their use for drugs approval and, especially, price and reimbursement is still limited. The present paper illustrates the discussion and recommendations of three interdisciplinary and multi-stakeholder Working Groups (WGs) on this topic.Method: The discussion, oriented by a report from the coordinators, focused on the role of PRO in the comparative evaluation of efficacy and risk, of PRE as an expression of preference for the drugs value components and of PRO and PRE in the regulatory process and national and regional access.Results: The results are reported as reflections and recommendations on the three topics.Conclusions: There is widespread consensus on the need to enhance the use of PRO and PRE, provided that (i) methodological and operational issues are addressed, (ii) PRO and PRE role in the regulatory and access process is clarified, (iii) representatives of patients and institutions are involved in a more structured way (iv) the actual role played in decision-making is clarified.

  • Open Access

    Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulators

    by Emma Diletta Stea, Mariateresa Pugliano, Roberta Gualtierotti, Monica Mazzucato, Luisa Santangelo, Giuseppina Annicchiarico, Alfredo Berardelli, Stefano Bianchi, Laura Bogliolo, Paolo Chiandotto, et al.


  • Open Access

    Diagnostic-therapeutic pathway and organizational model for gene therapy in the administration of congenital retinal dystrophies in real-life

    by Francesco Bandello, Maurizio Battaglia Parodi, Leonardo Colombo, Fabrizio Giansanti, Francesco Saverio Mennini, Marcello Pani, Francesco Parmeggiani, Ugo Procoli, Stanislao Rizzo, Annalisa Scopinaro, et al.

    Background: Leber congenital amaurosis is the first form of inherited retinal dystrophy (IRD) treated with a gene therapy approach using voretigene neparvovec (VN). To date, 42 patients have been treated, 25 of whom, treated at Clinica Oculistica Vanvitelli (Naples), have shown – after 45 days of treatment – a significant increase in dim-light visual function, a widening of the visual field, and an increase in central visual acuity. Objective: A workshop has been organized to foster rapid access, investigate the current organizational scenario, and identify a value framework suitable for making gene therapy delivery efficient in terms of efficacy, safety, and sustainability. Methods: The workshop involved 14 experts in clinical genetics, ophthalmology, and vitreoretinal surgery. All experts were subjected to questions related to three topics: diagnostic-therapeutic pathway of IRD patients, essential requirements for gene therapy delivery centres, and standardized model for therapy delivery. All contributions were judged to be of equal value. Results: The panel identified: the steps of the diagnostic pathway to achieve early diagnosis; the essential criteria that delivery centres must possess in terms of experience, multidisciplinary team, and technical equipment; a standardized model for VN administration. A network of few centres was identified as the best organizational model for VN delivery since it would ensure the gaining of experience and clinical excellence. Conclusion: This paper provides a perspective that can be used as a starting point to standardize the diagnostic-therapeutic pathway of IRD patients and define the essential requirements that centres must meet for VN administration.